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Abstract
Background: The elderly populations increase in world because of improved health status in communities, so
health and independency of seniors has become and will be one of the main priorities of public health systems.
Ageing have been associated with changes in body composition, including loss of muscle mass, loss of bone mass
and increase fat mass. Involuntary age related loss of muscle mass, sarcopenia,has been linked to functional
impairment and physical disability. Several definitions for sarcopenia have been presented based on the method of
measuring body composition, but an internationally accepted definition doesn’t presently exist yet.
In 2010, the European working group on sarcopenia developed a new definition for sarcopenia according to
measure muscle mass and muscle function. Several studies have been done about sarcopenia in world, but to our
knowledge this study is the first in Iran which is one of the largest countries of the Middle East that faces a fast
growing elderly population. The aim of this study is to evaluate sarcopenia and related risk factors in Iran according
new definition of sarcopenia.
Methods: This study will be conducted in two phase among elderly men and women over 55 years in the 6th
district of TehranThe first phase will be a population-based cross-sectional study to determine the frequency of
sarcopenia in the study population, and to conduct case finding for the second phase. The second phase will be a
case–control study to comparison the metabolic and inflammatory factors in sarcopenic and non sarcopenic groups.
The association between sarcopenia and major dietary pattern will be evaluated using factor analysis.
Conclusion: This study is the first study that evaluates sarcopenia and its risk factor in Iranian elderlies.
We discuss details of how we collect the data and appropriate instruments to measure muscle mass, muscle power
and muscle strength, and suitable cut- off to define sarcopenia in Iranian elderlies. We believe the result of our study
can be useful to health policy makers prepare the necessary infrastructure for elderly health improvements and
increase the quality of life in geriatric.
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Background
The world’s population is aging. It is estimated that by
the year 2050, the elderly population will triple from 600
million as it was in the year 2000 to more than two bil-
lion [1]. As a result, improving the health and indepen-
dency of seniors has become and will be one of the main
priorities of public health systems. World Health
Organization (WHO) has named 2012 the Year of
Health and Aging.
Aging is associated with changes in all organs including
body composition, skeletal muscle, and bone mass [2-4].
Muscle mass decreases approximately 3–8% per decade
after the age of 30 and this rate of decline is even higher
after the age of 60 [5]. This involuntary age related loss of
muscle mass was named for the first time in 1989 by Irwin
Rosenberg as Sarcopeny. The term Sarcopenia consists of
the Greek words sarks (flesh) and penia (loss) [6] and is
equivalent to a process that occurs during osteoporosis [7].
Sarcopenia imposes significant costs on the health care
system each year. It is the underlying cause of frailty [8],
the debilitating syndrome in aging, and the sixth cause
of death in people over 65 years [9]. Furthermore,
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Sarcopenia is a major risk factor of falling and disability
in the elderly [10]. Functional impairment and physical
disability in Sarcopenic people are 2 to 3 times more
likely. In the United States, costs related to complica-
tions of Sarcopenia was estimated to be more than 18.5
billion dollars in 2000 [11].
Several studies have discussed the mechanisms involved
in the development of Sarcopenia including alterations in
sex hormones, a decrease in protein synthesis, neuromuscu-
lar integrity changes, an increase in muscle fat content, re-
sistance to insulin, inappropriate physical activity and
inadequate nutrition [12]. Additionally, other studies have
emphasized the genetic role [13], inflammation, and oxida-
tive stress [14] in development of Sarcopenia.
Since 1989, several definitions for Sarcopenia have been
presented based on the method of measuring body compos-
ition. These methods include using bioempedance analysis,
dual x-ray absorptiometry, computed tomography, magnetic
resonance and measurement of total or partial body potas-
sium [15]. However, an internationally accepted definition of
Sarcopenia doesn’t presently exist yet [16]. In 2010, the
European Working Group on Sarcopenia (EWGSOP) devel-
oped a new definition for Sarcopenia. EWGSOP recom-
mends using the presence of both low muscle mass and low
muscle function (strength or performance) for diagnosis of
Sarcopenia in clinical and research tests [15]. EWGSOP sug-
gests three stages for Sarcopenia: The Pre-Sarcopenia stage
is characterized by low muscle mass without change in
muscle strength or performance. The second stage, Sarcope-
nia, is defined by low muscle mass plus low muscle strength
or low physical performance. The third stage, known as se-
vere Sarcopenia, is associated with the decrease of all of
three components, muscle mass, strength, and performance.
Researchers have studied the prevalence of sarcopenia
in various countries around the world including develop-
ing countries [17-20]. We try to use (EWGSOP) defin-
ition to study sacopenia in a country which has not been
studied before. We focus on Iran which is one the lar-
gest countries of the Middle East and is dealing a fast
growing elderly population. Our main objective is to
measure the prevalence of sarcopenia among Iranian
elderlies using the EWGSOP definition. In addition, we
try to evaluate the risk factors associated with sarcopenia
in our targeted population. Ultimately we aim to study
the role of diet, metabolic syndrome and inflamma-
tory markers on sarcopenia. This will help us recognize
the modifiable risk factors in dietary pattern of elderly
Iranians which in turn can be used in dietary recom-
mendations for sarcopenia prevention.
Method
Design and setting
This study will be conducted in collaboration with the
Nutrition School, Endocrinology and Metabolism
Research Institute of Tehran University of Medical
Sciences.
The project is consisted of two phases.
First phase
The first phase is a population-based cross-sectional
study, which will be conducted among elderly men and
women in the 6th district of Tehran a [21] in order to de-
termine the frequency of Sarcopenia in the study popu-
lation and to conduct case findings for the second
phase.
Second phase
The second phase will be a case–control study. The case
group includes participants with Sarcopenic criteria in
accordance with EWGSOP definition (prevalent cases).
Participants in the first phase who lacked the necessary
criteria for Sarcopenia will make up the control group.
Participants
Using cluster random sampling, 30 clusters in the 6th re-
gion of the Tehran Municipality will be determined in
collaboration with the Iran post office. The head of the
clusters will be selected based on a ten-digit postal code
and subjects will be asked for home interviews. Sampling
will be continued in each cluster in clockwise order until
the desired sample size is reached.
In each cluster, two individuals (one male, one female)
will be invited from each of the following age groups:
55–59, 60–64, 65–69, 70–74, and over 75 (a total of 10
persons in each cluster). During the home interviews,
these individuals will be briefed about the project and its
objectives and for those who agree to participate, clinic
appointments will be set. Participants will be asked to
comply with the following requirements prior to their
appointments: a) Participants should not be pregnant.
b) Participants will be required to fast for 10 hours
prior to testing. c) Participants should not take cal-
cium supplements two days prior to testing. d) Metal
objects (e.g. piercing, earrings, jewelry)are not allowed.
e) Participant should bring his/her medications.
Inclusion criteria
1. Participants should be at least 55 years old.
2. Participants will be required to have the ability to
move without crutches, walker or other assistive
devices.
3. There should be an absence of artificial limbs or limb
prosthesis.
4. There should be an absence of active cancer,
according to individual self report.
5. Three should be an absence of Congestive Heart
Failure (CHF), Chronic Obstructive Pulmonary
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Disorder (COPD), Chronic Renal Failure (CRF),
cirrhosis and liver failure (all based on the individual
self report).
First phase sample size
The population size will be 300 persons (power 80%, de-
sign effect 1.2, α =%5).
Second phase sample size
Our case group (prevalent cases) will consist of those
participants who are considered Sarcopenic based on the
EWGSOP definition in phase 1. Each participant in the
case group will then be matched with two participants
from the same age group who are not considered Sarco-
penic using the same EWGSOP definition.
The minimum sample size for the case group will be
30 persons, according to the comparison of protein in-
take between Appendicular Lean Mass’s first and second
quartiles [22]. The minimum sample size for the control
group will be 60.
The study protocol will be reviewed by Tehran Univer-
sity of Medical Sciences ethics committee.
Measurements
The following measures will be performed for each indi-
vidual in the clinic after obtaining a written consent: a
10 cc fasting blood sample will be taken for assessing
metabolic syndrome constituent. This consists of fasting
blood sugar(FBS), triglyceride(TG), and high density
lipoprotein (HDL) in first phase. Some portion of the
serum sample (2 ml) will be kept at −80°C for further
examinations in the second phase.
Questionnaires
Three questionnaires including, a general questionnaire,
a physical activity questionnaire, and a food frequency
questionnaire (FFQ) will be completed for each partici-
pant by a trained dietitian.
Participants will be asked about age, marital status,
education, past medical history, smoking, and alcohol
use in general questionnaires. The past medical history
includes a history of diseases such as stroke, myocardial
infarction, asthma, diabetes, and arthritis, as well as a
history of drug consumption such as oral sexual hor-
mones, statins, angiotensin convertin enzyme inhibitors,
and insulin. In order to adjust their effect on inflamma-
tion and the metabolic syndrome, participants will also
be asked about the consumption of aspirin, oral glucose-
lowering drugs, blood pressure-lowering drugs, cortico-
steroid and lipid lowering drugs.
The physical activity level will be evaluated by a short
form physical activity questionnaire (IPAQ) [23], which
will be translated into Persian. Participants will be asked
to report time spent on walking, moderate-intensity
activity, and vigorous-intensity activity during the week
prior to test. The physical activity data will be converted
to minute per week and expressed as a metabolic
equivalent (MET-min/week) according to IPAQ guide-
lines for data processing [24]. The participants with total
physical activity lower than 600 MET-minute/week will
be considered as low physical activity, the amount above
3000 MET-minute/week will be considered as high phys-
ical activity, and the amount between 600 to 3000 will
be considered as moderate physical activity.
The participants’ dietary intake will be assessed by
using 117 items in the semi-quantitative FFQ. The FFQ
consists of a list of food items with standard serving
sizes commonly used by Iranian consumers. Participants
will be asked to report their consumption frequency of
each food item during the year prior to the test accord-
ing to daily, weekly and monthly intervals. This FFQ has
been validated for 40–60 year old female residents of
Tehran by Esmaillzadeh et al. [25]. To examine the val-
idity and reliability of FFQ in the older population, we
have designed a pilot study.
Anthropometric and blood pressure measurement
Height will be measured in meters using a wall tape in
standing position without shoes. Participants’ weight
(in kg) will be assessed using a digital scale, while they
are minimally clothed. Waist circumference will be mea-
sured in the middle of lower rib margin and iliac crest,
standing and breathing normally. A general physician
will measure participants’ blood pressure in the sitting
position after 15 minutes rest using an analog sphygmo-
manometer. The first sound appearance will be consid-
ered as systolic blood pressure, and the disappearance of
sound will be diastolic blood pressure.
Body composition analysis
Muscle mass can be measured using a wide range of
devices such as magnetic resonance imaging, computed
tomography, dual x-ray absorptiometry, bioimpedance
analysis, and total or partial body potassium in lean
mass [15]. DXA is an attractive alternative method for
research and clinical use to distinguish fat, bone and
lean tissues [15]. This device can measure fat mass,
muscle mass, and bone mass of head, trunk, and ex-
tremities separately with minimal radiation exposure. In
this study we will use the DXA scanner (Discovery W S/
N 84430) to determine body composition for each per-
son. Participants will be ask to lie supine without move-
ment during imaging. The time which is required for
evaluation of each participant will be 15 minutes.
According to DXA results, we will calculate the appen-
dicular skeletal muscle mass for each participants as the
sum of upper and lower limb muscle mass (in kg) [26].
Since a large proportion of total body muscle mass is
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found in appendicular skeletal muscle, AST can accur-
ately represent the total muscle mass [27]. In order to
eliminate the effect of height on total muscle mass, the
relative skeletal muscle mass will be computed as the
ratio of ASM to squared height (ASM/height2) [6].
Based on the findings of other studies in the literature,
the relative skeletal muscle mass less than 7.26 kg/m2
for men and 5.5 kg/m2 for women will be considered ab-
normal [28].
Muscle strength measurement
There are several techniques for estimation of the muscle
strength, such as handgrip strength, knee flexion/exten-
sion, and peak expiratory flow. Isometric grip strength is a
good simple measure of muscle strength, which is
known to be strongly correlated with leg strength
[15]. Isometric grip strength can be measured by two
well known devices, the Jamar dynamometer and the
Martin vigorimeter [29]. Unfortunately, because of
the lack of access to both of these devices, we will
have to use a squeeze bulb dynamometer (c7489-02
Rolyan), which is a pneumatic instrument like a modi-
fied sphygmomanometer and is calibrated in pounds
per square inch (psi). The squeeze bulb dynamometer
measures isotonic muscular action instead of isomet-
ric strength, which is measured by the widely used
Jamar dynamometer or Martin vigorimeter. However,
studies have shown a strong correlation between the
two measurements [30].
In accordance with the recommendations of American
Society of Hand Therapists, we will measure grip
strength with maximum voluntary contractions for each
participant. We will then repeat the measurement three
times for each hand with a 30-second rest time in be-
tween each trial. The average of maximum values for the
left and right hands will be considered as the measure of
the participant’s muscle strength. The cutoff value for
muscle strength will be obtained from previous studies
[31].
Muscle performance
Several tests have been suggested in the literature for
evaluating muscle performance including, Short Physical
Performance Battery (SPPB), usual gait speed, 6-min
walk test and the stair climb power test. We will evalu-
ate participants’ muscle power by performing a 4-m
course gait speed test which is a part of SPPB, but it can
also be used as a single parameter for clinical practice
and research [15]. Each participant will be asked to walk
at his/her usual pace to the other end of the 4-meter
course. The time will be recorded by chronometer in
seconds. Participants with gait speeds lower than
0.8 m/s will be considered to be at high risk of
Sarcopenia [15].
Definition and cut off point
Sarcopenia
We will use EWGSOP definition of sarcopenia to define
the case group. According to this definition, individuals
with abnormal ASM are considered as Pre-Sarcopenic.
A Sarcopenic person is an individual who is identified as
Pre-Sarcopenic and also has abnormal muscle strength
or muscle performance. Those with all three abnormal
criteria will be considered to be severely Sarcopenic [15].
Metabolic syndrome
Metabolic syndrome will be defined as the presence of
abdominal adiposity (wc> 94 cm in men and wc> 80 cm
in women) plus any two of the following components as
recommended by the International Diabetes Federation:
low serum HDL cholesterol (< 40 mg/dl in men and < 50
in women) or specific treatment for this lipid abnormality,
high serum triacylglycerol concentrations ≥ 150 mg/dl or
lowering triglyceride drugs consumption, raised blood
pressure ≥ 130/85 or treatment of previously diagnosed
hypertension, elevated fasting plasma glucose ≥ 100 orpre-
viously diagnosed type 2 diabetes [32].
Inflammatory marker
Studies have focused on the role of inflammatory cyto-
kines especially IL6, TNFα, CRP in the progression of
muscle loss in recent years [11,33] so we will measure
this cytokine for both case and control group using
appropriate kits.
Dietary pattern
Unlike the traditional analyses which examine the rela-
tion between a single nutrient and a particular disease,
dietary pattern analysis focuses on the relationship be-
tween diet and the risk of a disease. Dietary pattern is a
better method to evaluate the association of nutrition
and the risk of a disease for several reasons. First, each
food is a combination of several nutrients. Second, the
correlation among some nutrients is very high, so distin-
guishing the relationship between food and the disease
will be difficult. Third, the effect of a single nutrient will
be hard to detect due to the small amount, whereas the
cumulative effect of nutrients in a dietary pattern may
be large enough to detect [34]. All these have led to a
growing interest among dietitians for using dietary pat-
tern analysis to evaluate the relationship of food and
chronic disease.
Data processing & analysis
The nutritional intake of each food item will be con-
verted to gram/day and dietary analysis will be con-
ducted using the Iranian food composition table [35]
and the USDA food composition data [36]. We will
identify major dietary patterns using factor analysis and
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the FFQ data. To do so, we first group similar food items
in the FFQ so that each food group is consumed by at
least 10 participants. We will then use principle compo-
nent analyses to calculate each group’s loading factor
based on major dietary patterns. A summary score will
be obtained for each pattern and will be used to investi-
gate the relationship between dietary pattern and
disease.
After examining the distributional assumption (nor-
mality) of data, we will compare the case and control
groups using parametric tests as well as nonparametric
methods. We will use the appropriate control methods
and modeling techniques to eliminate the effect of con-
founding factors. The entire analysis will be done using
SPSS software version 16 (SPSS Inc., Chicago IL) or
STATA software.
Conclusion
Sarcopeny is a multifactorial disease which is associated
with a decrease in skeletal muscle mass and can be a
major risk factor for development of frailty. It increases
the elderly population’s disability and dependency and
may impose high costs to health systems. Studying risk
factors of Sarcopenia can be useful to prevent or delay
the development of this disease.
There are plenty of studies in literature which state
the risk factors associated with Sarcopenia in developed
courtiers. However, not enough attention has been paid
to this issue in developing countries. We will try to con-
tribute to the literature by providing more information
on the status of this disease and also its risk factors
among elderly population in Iran. Due to the growing
elderly population, attention to elderly health is one of
the priorities of the health system in Iran. To our know-
ledge, this is the first study which focuses on Sarcopenia
in community-dwelling elderly Iranians. We believe the
results of our study can be useful to the public health
system, Ministry of Health and Medical Education, and
Seniors Health Administration. Our results can help pol-
icy makers prepare the necessary infrastructure for eld-
erly health improvements and increase the quality of life
in geriatric patients.
Endnote
aAccording to 2006 Census, the district has a popula-
tion of 237,292 which is about 3.3% of total population
of Tehran.
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